Trial Profile
A Multi-centre Phase III Study to Evaluate Pre-emptive Tenofovir for Prevention of Hepatitis B Virus Reactivation in HBsAg Negative/Anti-HBc Positive Individuals Undergoing Anti-CD20-based Chemotherapy for Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 02 Dec 2021
Price :
$35
*
At a glance
- Drugs Tenofovir (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- 10 Dec 2019 Planned End Date changed from 1 Jun 2020 to 1 Feb 2021.
- 10 Dec 2019 Planned primary completion date changed from 1 Jun 2020 to 1 Feb 2021.
- 28 Sep 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2020.